SDGR — Schrodinger, Inc.

Is SDGR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Health Information Services

Overbought As of October 3, 2026

Schrodinger, Inc. (SDGR) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Health Information Services) last closed at $30.31. The rating moved from Neutral to Overbought on October 2, 2026.

See all overbought Healthcare stocks →

AI analysis

Schrodinger, Inc. combines a differentiated physics-based molecular design platform with expanding software subscription revenue and visible pharma collaborations. The company's competitive moat is rooted in its validated simulation tools and IP, which position it to benefit from continued adoption of in‑silico drug discovery and AI-enabled workflows. Near-term growth depends on converting collaborations to recurring licensing and milestone streams while achieving margin expansion. Key catalysts include new large-scale partnerships, milestone receipts, and broader recovery in biotech funding. Primary concerns are execution risk on commercial adoption, competition from AI-native drug design firms, and sensitivity to macro-driven R&D budget cuts; these factors make revenue lumpy and valuation-sensitive in the short term.

Key factors

  • Proprietary physics-based molecular simulation platform with differentiated IP that supports both software licensing and discovery collaborations.
  • Recurring and expanding software/subscription revenue from enterprise customers (pharma/biotech), driving higher-margin revenue mix over time.
  • Growing adoption of in-silico design and AI/ML-enabled workflows in drug discovery, which increases addressable market for Schrodinger's tools.
  • Strategic partnerships and collaborations with large pharma provide near-term revenue visibility and validation of the platform.
  • Potential for downstream upside if in-house discovery programs or collaboration milestones monetize; optionality from licensing and milestone payments.
  • Relative insulation from direct drug pricing policy (IRA) impacts compared with pure therapeutics companies, while still benefiting from broader biotech funding when risk appetite returns.

Risks

  • Sustained macro-driven risk aversion and biotech funding pullback that reduces R&D budgets and delays customer purchases or collaborations.
  • High execution risk on converting proof-of-concept collaborations into recurring license revenue and milestone monetization.
  • Intensifying competition from AI-first drug design startups and incumbents improving in-house computational capabilities, pressuring pricing and win rates.
  • Ongoing unprofitability and cash burn could necessitate dilutive financing if revenue growth / margin expansion slows.
  • Customer concentration and long enterprise sales cycles that can create lumpy revenue and visibility challenges.
  • Regulatory, reimbursement, or policy shifts that indirectly reduce pharmaceutical R&D spend or change collaborator economics.
  • Market sentiment volatility tied to broader biotech and technology sector moves, increasing share-price sensitivity to headlines.

See today's live rating, score and targets

Members see the live hourly rating for SDGR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.